Ria Health Raises Growth Capital to Accelerate Access to Patient-Driven AUD Treatment
2024 SV Therapeutics Impact & ESG Report
Read More
Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas
Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System
SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise
Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure
Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
Read More
SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion
Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation
QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
10 March 2020Portfolio NewsBicycle Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates
9 March 2020Portfolio NewsAVROBIO Receives Orphan Drug Designation from U.S. FDA for AVR‑RD‑04 for Cystinosis- 9 March 2020Portfolio NewsDeciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2019 Financial Results
4 March 2020Portfolio NewsSV Health Investors joins Xilio Therapeutics’ $100.5 million Series B financing - proceeds will advance XTX201 and XTX101 into the clinic while expanding Xilio’s cytokine pipeline
2 March 2020Portfolio NewsEvelo Biosciences Announces Biomarker Data Showing EDP1815 is an Orally Delivered Dual Cytokine Inhibitor for Inflammatory Diseases- 2 March 2020Portfolio NewsAkrevia Therapeutics Rebrands as Xilio Therapeutics and Announces $100.5 Million Series B Financing
- 25 February 2020Portfolio NewsBicycle Therapeutics Announces Exclusive Strategic Collaboration with Genentech to Develop and Commercialize Bicycle®-based Immuno-oncology Therapies
- 7 January 2020Portfolio NewsBicycle Therapeutics and Cancer Research UK to Collaborate on Development of New Bicycle® Immuno-oncology Candidate, BT7401
1 March 2019SV NewsSV included in PitchBook news' top 8 VC investors in Eu biotech startups- 27 December 2018SV NewsSV Health Investors listed 6th in Forbes list of VC's making the most investments in healthcare startups
- 1 June 2017Portfolio NewsBicycle Therapeutics Closes £40 Million ($52 Million) in Series B Financing to Advance Clinical Pipeline
27 April 2017Portfolio NewsArsanis Completes $45.5 Million Series D Financing
